FDA Approval in TGCT, Breakthrough Designation in Melanoma, and More

Source: OncLive, September 2019

An FDA approval in tenosynovial giant cell tumor, a breakthrough therapy designation in melanoma, and encouraging findings in trials in bladder cancer, lung cancer, and a cell-free DNA assay.

Welcome to OncLive News Network! I’m Kristi Rosa.

The FDA has approved pexidartinib, known by the trade name Turalio, for the treatment of adult patients with symptomatic tenosynovial giant cell tumor that is associated with severe morbidity or functional limitations and not responsive to improvement with surgery.

Read the original full article